Search
tipiracil/trifluridine; TAS-102 (Lonsurf)
Indications:
- treatment of metastatic colorectal adenocarcinoma [1]*
* improves life-expectancy 7.1 vs. 5.3 months in patients refractory to conventional therapy [1]
Contraindications:
- pregnancy & lactation
Pregnancy category: X :Safety in lactation: -
Monitor:
- complete blood count (CBC) prior to each treatment
Adverse effects:
- anemia
- neutropenia
- thrombocytopenia
- weakness
- fatigue
- anorexia
- nausea/vomiting
- diarrhea
- abdominal pain
- fever [2]
General
pharmacologic combination
Database Correlations
PUBCHEM cid=9829639
References
- Mayer RJ et al.
Randomized trial of TAS-102 for refractory metastatic
colorectal cancer.
N Engl J Med 2015 May 14; 372:1909
PMID: 25970050
http://www.nejm.org/doi/full/10.1056/NEJMoa1414325
- FDA News Release. September 22, 2015
FDA approves new oral medication to treat patients with
advanced colorectal cancer.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm
Components
tipiracil
trifluridine (Viroptic)